DeepMed Research

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Fractional Urate Excretion in Nonedematous Hyponatremia

Not Applicable

Withdrawn

Conditions: SIADH
Cerebral Salt-wasting Syndrome
Cerebral Hyponatremia
Reset Hypothalamic Osmostat

Interventions: Drug: Tolvaptan in euvolemic hyponatremia

First Posted Date: 2011-08-29

Last Posted Date: 2019-02-06

Lead Sponsor: NYU Langone Health

Registration Number: NCT01425125

Locations: 🇺🇸
Winthrop-University Hospital, Mineola, New York, United States

Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35

Completed

Conditions: Diabetes

First Posted Date: 2011-08-26

Last Posted Date: 2014-04-01

Lead Sponsor: NYU Langone Health

Target Recruit Count: 55

Registration Number: NCT01423877

Locations: 🇺🇸
Bellevue Hospital Center, New York, New York, United States

Study of Botulinum Toxin and Recovery of Hand Function After Stroke

Phase 3

Completed

Conditions: Stroke With Hemiparesis

Interventions: Drug: Botulinum Toxin commonly known as BOTOX®
Drug: Placebo

First Posted Date: 2011-08-23

Last Posted Date: 2019-06-20

Lead Sponsor: NYU Langone Health

Target Recruit Count: 16

Registration Number: NCT01422161

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Study of the Recovery of Muscle Function in the Arm/Hand After a Stroke

Not Applicable

Completed

Conditions: Stroke
Hemiparesis

Interventions: Other: Conventional Occupational Therapy
Other: Simultaneous Bimanual training

First Posted Date: 2011-08-23

Last Posted Date: 2020-08-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 53

Registration Number: NCT01422005

Locations: 🇺🇸
New York Univeristy School of Medicine, New York, New York, United States

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

Phase 1

Completed

Conditions: Breast Cancer
Recurrent Breast Cancer
Metastatic Breast Cancer

Interventions: Radiation: Radiation
Drug: Imiquimod
Drug: Cyclophosphamide

First Posted Date: 2011-08-22

Last Posted Date: 2021-11-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 31

Registration Number: NCT01421017

Locations: 🇺🇸
New York University Medical Center, New York, New York, United States

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Phase 2

Completed

Conditions: Neurofibromatosis Type II

Interventions: Drug: Everolimus (RAD001) , Afinitor®

First Posted Date: 2011-08-18

Last Posted Date: 2017-07-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT01419639

Locations: 🇺🇸
New York University Medical Center, New York, New York, United States

Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography

Phase 4

Completed

Conditions: Diabetes Mellitus
Coronary Artery Disease

Interventions: Other: hold hypoglycemic meds

First Posted Date: 2011-08-18

Last Posted Date: 2012-06-12

Lead Sponsor: NYU Langone Health

Target Recruit Count: 351

Registration Number: NCT01419652

Locations: 🇺🇸
VA New York Harbor, New York, New York, United States

Safety Study of Pyridostigmine in Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: Pyridostigmine Bromide

First Posted Date: 2011-08-12

Last Posted Date: 2017-07-31

Lead Sponsor: NYU Langone Health

Target Recruit Count: 33

Registration Number: NCT01415921

Locations: 🇺🇸
New York University Langone Medical Center, New York, New York, United States

Effects of Weight Loss on Cardio-respiratory Function

Completed

Conditions: Cardiovascular Abnormalities
Obesity

First Posted Date: 2011-08-05

Last Posted Date: 2014-12-02

Lead Sponsor: NYU Langone Health

Target Recruit Count: 150

Registration Number: NCT01410487

Locations: 🇺🇸
Bellevue Hospital Ambulatory Cinic - Suite 1D, New York, New York, United States

3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women

Not Applicable

Withdrawn

Conditions: BRCA1 Mutation
BRCA2 Mutation
Breast Cancer

Interventions: Device: 3.0-T MRI
Procedure: biopsy

First Posted Date: 2011-08-04

Last Posted Date: 2012-04-05

Lead Sponsor: NYU Langone Health

Registration Number: NCT01409226

Locations: 🇺🇸
NYU Medical Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy